Skip to main content

Vemurafenib

  • Chapter
  • First Online:
Book cover Small Molecules in Oncology

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 201))

Abstract

The activating BRAF mutation V600E and related mutations in this codon are most important for the activation of the RAS/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signalling pathway in melanoma. BRAF V600E mutations have been detected in ~40 % of melanoma patients and BRAF V600K mutations in ~5 % of melanoma patients. Activation of the MAPK pathway results in continuous stimulation of cell proliferation and inhibits programmed cell death. Vemurafenib (PLX4032) was developed as a low molecular weight molecule for the inhibition of the mutated serine threonine kinase BRAF, and it selectively binds to the ATP-binding site of BRAF-V600E kinase and inhibits its activity. The biochemical affinity of vemurafenib for mutated BRAF translates to potent inhibition of ERK phosphorylation and of cell proliferation exclusively in BRAF-mutant cell lines. In animal model experiments, it was demonstrated that vemurafenib achieved tumour regressions in cells harbouring the BRAF V600E mutation. The clinical trials with vemurafenib in unresectable metastatic melanoma in phase I, II, and III for patients harbouring BRAF V600E mutations demonstrated all unexpected high objective response rates ranging between 50 and 80 %. Median progression-free survival was prolonged from two months with dacarbazine to seven months with vemurafenib, and median overall survival was respectively prolonged from 9 to 14 months. A major problem that remains is the development of resistance to vemurafenib treatment after several months in the majority of patients, and multiple resistance mechanisms have already been described. Under vemurafenib treatment, about 25 % of patients developed cutaneous squamous cell carcinomas of the keratoacanthoma type with low invasive potential and without occurrence of metastasis. The overall tolerability of the drug was quite good, and a number of patients remained on treatment for long times. As other solid tumours like papillary thyroid cancer, colorectal cancer, non-small-cell lung cancer, and ovarian cancer likewise harbour BRAF mutation, vemurafenib is also tested in these entities. In future, combinations of vemurafenib with other kinase inhibitors and with immunotherapies will improve its therapeutic potential.

Keywords

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abusaif S, Jradi Z, Held L et al (2013) S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma. Melanoma Res 2013, Epub ahead of print

    Google Scholar 

  • Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199–6206

    Article  PubMed Central  PubMed  Google Scholar 

  • Bollag G, Hirth P, Tsai J et al (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596–599

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Carlson JA, Ross JS, Slominski A et al (2005) Molecular diagnostics in melanoma. J Am Acad Dermatol 52:743–775

    Article  PubMed  Google Scholar 

  • Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Chapman PB, Hauschild A, Robert C et al (2012) Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol 30:8502

    Google Scholar 

  • Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954

    Article  CAS  PubMed  Google Scholar 

  • Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T (2012) BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 366:2038–2040

    Article  PubMed  Google Scholar 

  • Eigentler TK, Garbe C (2006) Malignant melanoma: classification and staging of malignant melanoma. Front Radiat Ther Oncol 39:149–158

    PubMed  Google Scholar 

  • European Medicines Agency (2013) Zelboraf—Annex I—Summary of product characteristics. 19 June 2013

    Google Scholar 

  • Finck SJ, Giuliano AE, Morton DL (1983) LDH and melanoma. Cancer 51:840–843

    Article  CAS  PubMed  Google Scholar 

  • Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809–819

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Gautschi O, Pauli C, Strobel K et al (2012) A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 7:e23–e24

    Article  PubMed  Google Scholar 

  • Gogas H, Eggermont AM, Hauschild A et al (2009) Biomarkers in melanoma. Ann Oncol 20(6):vi8–vi13

    PubMed Central  PubMed  Google Scholar 

  • Greenman C, Stephens P, Smith R et al (2007) Patterns of somatic mutation in human cancer genomes. Nature 446:153–158

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hauschild A, Engel G, Brenner W et al (1999) S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56:338–344

    Article  CAS  PubMed  Google Scholar 

  • Hoffmann-La Roche Ltd (2012) Roche’s Zelboraf receives EU approval for the treatment of people with deadly form of skin cancer. http://www.roche.com/media/media_releases/med-cor-2012-02-20.htm

  • Kim KB, Cabanillas ME, Lazar AJ et al (2013) Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid 23:1277–1283

    Article  CAS  PubMed  Google Scholar 

  • Kopetz S, Desai J, Chan E et al (2010) PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumours. J Clin Oncol 28:3534

    Article  Google Scholar 

  • Mao M, Tian F, Mariadason JM et al (2013) Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 19:657–667

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M et al (2002) Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 62:7001–7003

    CAS  PubMed  Google Scholar 

  • Oberholzer PA, Kee D, Dziunycz P et al (2012) RAS mutations are associated with the development of cutaneous squamous cell tumours in patients treated with RAF inhibitors. J Clin Oncol 30:316–321

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Peyrade F, Re D, Ginet C et al (2013) Low-dose vemurafenib induces complete remission in a case of hairy-cell leukaemia with a V600E mutation. Haematologica 98:e20–e22

    Article  PubMed Central  PubMed  Google Scholar 

  • Peyssonnaux C, Eychene A (2001) The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93:53–62

    Article  CAS  PubMed  Google Scholar 

  • Pflugfelder A, Eigentler TK, Keim U et al (2011) Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma. PLoS One 6:e16882

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Prahallad A, Sun C, Huang S et al (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483:100–103

    Article  CAS  PubMed  Google Scholar 

  • Schreck R, Rapp UR (2006) Raf kinases: oncogenesis and drug discovery. Int J Cancer 119:2261–2271

    Article  CAS  PubMed  Google Scholar 

  • Shah N, Iyer RM, Mair HJ et al (2013) Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process. J Pharm Sci 102:967–981

    Article  CAS  PubMed  Google Scholar 

  • Sirott MN, Bajorin DF, Wong GY et al (1993) Prognostic factors in patients with metastatic malignant melanoma: a multivariate analysis. Cancer 72:3091–3098

    Article  CAS  PubMed  Google Scholar 

  • Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707–714

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Tanaka H, Deng G, Matsuzaki K et al (2006) BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer. Int J Cancer 118:2765–2771

    Article  CAS  PubMed  Google Scholar 

  • Tiacci E, Trifonov V, Schiavoni G et al (2011) BRAF mutations in hairy-cell leukemia. N Engl J Med 364:2305–2315

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Tie J, Gibbs P, Lipton L et al (2011) Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 128:2075–2084

    Article  CAS  PubMed  Google Scholar 

  • U.S. Food and Drug Administration (2011) FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer. http://www.roche.com/media/media_releases/med-cor-2012-02-20.htm

  • Weide B, Elsasser M, Buttner P et al (2012) Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer 107:422–428

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Xing M (2007) BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742–762

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Claus Garbe .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Garbe, C., Abusaif, S., Eigentler, T.K. (2014). Vemurafenib. In: Martens, U. (eds) Small Molecules in Oncology. Recent Results in Cancer Research, vol 201. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54490-3_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54490-3_13

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-54489-7

  • Online ISBN: 978-3-642-54490-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics